Co-localization of stanniocalcin-1 ligand and receptor in human breast carcinomas
Co-localization of stanniocalcin-1 ligand and receptor in human breast carcinomas
复制标题
DOI：
10.1016/j.mce.2003.10.042
复制
发表时间：
2004-01-15
影响因子：
4.1
通讯作者：
Wagner, GF
中科院分区：
文献类型：
--
作者：
McCudden, CR;Majewski, A;Wagner, GF
斯钙素-1 (STC1) 是一种新型多肽激素，对靶细胞线粒体具有代谢作用。最近的研究表明，STC1基因在原发性乳腺肿瘤中表达上调，并与雌激素受体共表达。在本报告中，我们证明了 STC1 及其受体在侵袭性和非侵袭性人类乳腺导管癌中的组织学共定位。对 58 例恶性乳腺活检的分析显示，91% 的病例中 STC1 及其受体共定位于癌细胞。因此，该研究表明，在乳腺癌中，STC1 在自分泌反馈环路中发出信号，并开启了肿瘤细胞以与非恶性细胞大致相同的方式隔离它的可能性。这些数据进一步支持了 STC1 在乳腺癌中发挥作用的观点，并且它可能被证明是一种新的诊断和预后标志物以及潜在的治疗靶点。 (C) 2003 Elsevier Ireland Ltd. 保留所有权利。
Stanniocalcin-1 (STC1) is a new polypeptide hormone that has metabolic effects on target cell mitochondria. Recent studies have shown that the STC1 gene is upregulated in primary breast tumors and co-expressed with the estrogen receptor. In this report we have demonstrated the histological co-localization of STC1 and its receptor in invasive and non-invasive human mammary gland ductal carcinomas. Analysis of 58 malignant breast biopsies revealed that STC1 and its receptor co-localized to cancer cells in 91% of cases. The study therefore reveals that in breast carcinomas STC1 signals in an autocrine feedback loop and opens up the possibility that it may be sequestered by neoplastic cells in much the same manner as it is by non-malignant cells. The data further supports the notion that STC1 plays a role in breast cancer and that it may prove to be a novel diagnostic and prognostic marker, and potential therapeutic target. (C) 2003 Elsevier Ireland Ltd. All rights reserved.